Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy A Dawson

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Urology|January 30, 2004
Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancerNancy A Dawson, Susan F Slovin
Expert Opinion on Biological Therapy|March 14, 2014
Sipuleucel-T and immunotherapy in the treatment of prostate cancerNancy A Dawson, Erin E Roesch
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Importance of serum hemoglobin in hormone refractory prostate cancerRobin T Vollmer, Philip W Kantoff, Nancy A Dawson, et al.
BMC Cancer|October 26, 2025
Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysisAurmin J Amirmokri, Christopher A Loffredo, Kepher H Makambi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinomaNancy A Dawson, Chuanfo Guo, Richard Zak, et al.
Journal of Managed Care & Specialty Pharmacy|January 27, 2017
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or EnzalutamideDominic Pilon, Ajay S Behl, Lorie A Ellis, et al.
Journal of Medical Economics|October 8, 2019
Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured populationBingcao Wu, Sophia S Li, Ji Song, et al.
American Health & Drug Benefits|June 20, 2017
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or ChemotherapyDominic Pilon, Ajay S Behl, Lorie A Ellis, et al.
European Urology|December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trialNicholas D James, Armelle Caty, Michael Borre, et al.
Cancer|December 24, 2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara, Frederick J Meyers, Lisa Y Law, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Urology|January 30, 2004
Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancerNancy A Dawson, Susan F Slovin
Expert Opinion on Biological Therapy|March 14, 2014
Sipuleucel-T and immunotherapy in the treatment of prostate cancerNancy A Dawson, Erin E Roesch
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Importance of serum hemoglobin in hormone refractory prostate cancerRobin T Vollmer, Philip W Kantoff, Nancy A Dawson, et al.
BMC Cancer|October 26, 2025
Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysisAurmin J Amirmokri, Christopher A Loffredo, Kepher H Makambi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinomaNancy A Dawson, Chuanfo Guo, Richard Zak, et al.
Journal of Managed Care & Specialty Pharmacy|January 27, 2017
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or EnzalutamideDominic Pilon, Ajay S Behl, Lorie A Ellis, et al.
Journal of Medical Economics|October 8, 2019
Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured populationBingcao Wu, Sophia S Li, Ji Song, et al.
American Health & Drug Benefits|June 20, 2017
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or ChemotherapyDominic Pilon, Ajay S Behl, Lorie A Ellis, et al.
European Urology|December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trialNicholas D James, Armelle Caty, Michael Borre, et al.
Cancer|December 24, 2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara, Frederick J Meyers, Lisa Y Law, et al.
Pageof 6